MEPSGEN US, Inc., a global innovator in drug delivery system platforms, announced the launch of NanoCalibur® Mini, an automated system for small-volume nanoparticle formulation designed for...

Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, announced the strategic acquisition of PULMOTREE, a Munich, Germany-based life science company specializing...

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announced the launch of the clinician-directed,...

AptarGroup, Inc. a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced the appointment of Virginie Maes as President of Aptar Pharma,...

Zai Lab Limited an innovation-driven, global biopharma company, shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination...

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new...

BD a leading global medical technology company, announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello™ Vascular...

Nordic Pharma, Inc., a subsidiary of SEVER Life Sciences B.V., will be held at the annual meeting of the American Academy of Ophthalmology from 9 to 12. October in New Orleans, Louisiana, introduce...

Arkayli BioPharma Inc. a biopharmaceutical company dedicated to developing innovative therapies for rare dermatologic conditions, announced that the U.S. Food and Drug Administration (FDA) has...

Carterra®, a leading provider of high-throughput surface plasmon resonance (HT-SPR™) platforms for antibody and small molecule drug discovery, announced a research collaboration with AstraZeneca to...

MedaSystems, a SaaS platform for managing Expanded Access, Post-Trial Access and Investigator-Initiated Study programs, announced the release of MedaSystems Version 3.3, one of the company’s most...

Dr. Oregonin Inc. announced that it has completed U.S. Food and Drug Administration (FDA) registration for OLTIS DENTAL-X, paving the way for its official commercial entry into the North American...